All About Multiple Sclerosis

More MS news articles for October 2002

The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: I. The evidences for the use of immunossupressive agents, plasma exchange and autologous hematopoietic stem cell transplantation

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12364965&dopt=Abstract

Free Full Text In Portugese:
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2002000500035&lng=en&nrm=iso

Arq Neuropsiquiatr 2002 Sep;60(3B):869-874
Callegaro D, Lana-Peixoto MA, Moreira MA, Marchiori PE, Bacheschi LA, Arruda WO, Campos GB, Lino AM, Melo AS, Rocha FC, Ferreira ML, Ataide L Jr, Maciel DR.

Since the sixties immunosuppressive agents have been used in the treatment of multiple sclerosis as there was cumulating evidence of the inflammatory nature of the disease.

Cyclophosphamide, azathioprine and methotrexate have been the most frequently employed drugs whereas other agents such as cyclosporine and cladribine have been recently tested for RRMS.

Mithoxantrone, on the other hand, was approved by the FDA for treatment of aggressive forms of the disease.

Other immunointerventions such as plasma exchange and autologous hematopoietic stem cell transplantation have recently been employed in some special circumstances.

This paper analyses the most important published data on the use of the immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation according to the classes of evidences and types of recommendations of these drugs and immunointerventions.

It provides sufficient information to support the guidelines expressed in the BCTRIMS Expanded Consensus on Treatment of MS.